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Evaluation of phenylethylamine type entactogens and their 
metabolites relevant to ecotoxicology – a QSAR study
The impact of the selected entactogens and their o-quinone 
metabolites on the environment was explored in QSAR stud-
ies by the use of predicted molecular descriptors, ADMET 
properties and environmental toxicity parameters, i.e., acute 
toxicity in Tetrahymena pyriformis (TOX_ATTP) expressed as 
Th_pyr_pIGC50/mmol L–1, acute toxicity in Pimephales prome-
las, the fathead minnow (TOX_FHM) expressed as Minnow 
LC50/mg L–1, the acute toxicity in Daphnia magna (TOX_DM) 
expressed as Daphnia LC50/mg L–1 and bioconcentration fac-
tor (BCF). 
The formation of corresponding o-quinones via benzo-dioxo-
lone ring, O-demethylenation was predicted as the main 
metabolic pathway for all entactogens except for 
1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)propan-2-amine 
(DiFMDA). The least favourable ADMET profile was re-
vealed for N-(1-(benzo[d][1,3]dioxol-5-yl)propan-2-yl)-O-
methylhydroxylamine (MDMEO). 
QSAR studies revealed significant linear correlations be-
tween MlogP of entactogens and MlogP of o-quinone me-
tabolites (R = 0.99), and Th_pyr_pIGC50/mmol L–1 (R = 0.94), 
also their MlogPs with Minnow_LC50/mg L–1 (R = 0.80 and R = 
0.78), BCF (R = 0.86 and R = 0.82) and percentage of o-qui-
nones’ yields (R = 0.73 and R = 0.80). Entactogens were pre-
dicted as non-biodegradable molecules, whereas the majo-
rity of their o-quinones were biodegradable.
Keywords: entactogens, ecstasy, ADMET, CYP metabolism, 
ecotoxicity, QSAR
Entactogens or empathogens are psychoactive substances that arouse a great interest 
of individuals who abuse these drugs but also the interest of health professionals, espe-
cially those who are involved in psychotherapy. Entactogens are used for both basic and 
clinical research, and experimental therapy, but also in recreational and psychospiritual 
settings where this practice is illicit or strictly regulated due to health concerns. Millions 
of people worldwide consume entactogens as recreational drugs at rave parties because 
they induce the feeling of euphoria, sharpened sensory perception and a greater capacity 
for social interactions (1).
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The new therapeutic class under the term „entactogens“ was proposed by Nichols 
based on unique human psychopharmacological effects of 3,4-methylendioxymetham-
phetamine (MDMA) and N-methyl-1(1,3-benzodioxol-5-yl)-2-butanamine (MBDB) which 
were distinct to hallucinogens (2).
In this class of psychoactive drugs, the MDMA (commonly known as ‘’ecstasy’’, ‘molly’’, 
‘’ADAM’’ or ‘’XTC’’, etc.) is the prototypical entactogen molecule, the most famous and the 
first “designer drug” which became widely used despite being illegal, together with the 
related 3,4-methylendioxyamphetamine (MDA) (3). Pharmacologically, MDMA produces 
a specific and distinct extroverted mental state with experiences of emotional communion, 
oneness, relatedness, emotional openness, i.e., empathy or sympathy. MDMA was first 
synthesized in 1912 as an intermediate in the production of other chemical substance, 
however, in the latter part of the 20th century, it became the most widely studied and 
recrea tionally used entactogen, even though it was put on the list of Schedule I controlled 
substances in the USA in 1985 as a drug with a high potential of abuse (4, 5). 
A unique profile of prosocial and interpersonal effects of entactogens is a consequence 
of the combination of catecholaminergic effects of methamphetamine, a precursor of 
MDMA, and the serotonergic effect of psychedelics. Evidence for the distinction of entac-
togens from both methamphetamine and psychedelics (Fig. 1) comes from structure-activ-
ity relationship (SAR) studies and animal models (6, 7).
Extensive literature search on the MDMA’s mechanism of action (8–11) has come to 
characterize it as a drug with multiple mechanisms, that involve altering the activity of 
neurotransmitter amines in the brain, i.e., serotonin, dopamine and norepinephrine, but the 
final consensus is that the distinctive entactogenic effects arise primarily from the release of 
neurotransmitter serotonin which likely contributes to the recreational use (12–15). 
Although marked as a drug with high abuse potential which impacted its clinical re-
search in last decade of the 20th century, a growing body of evidence later indicates that 
Fig. 1. Different phenylethylamine derivatives with hallucinogen (mescaline), stimulant (amphet-
amine and methamphetamine) and entactogen properties (MDA and MDMA)
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MDMA may have therapeutic applications (6, 16). To date, the most clinical MDMA research 
in patients has focused on MDMA-assisted psychotherapy for the treatment of posttrau-
matic stress disorder (PTSD) (17–19), whereas other potential applications include treatment 
of social anxiety in autism (20) and alcoholism-associated disorders (5), as well as the use in 
palliative care (21). After successful completion of Phase II trials, MDMA is included in 
Phase III of the drug development in 2018 with the set plan of licensing until 2021 for PTSD 
therapy by the FDA and EMA (22). 
Since being introduced in many countries in the 1980s and despite the illegal status, 
MDMA pills became the most popular „street drug“ and were often linked to rave and club 
parties where the misuse of MDMA and other illicit drugs at the same time has caused very 
often serious adverse reactions and fatal outcomes. Consequently, most of the efforts in the 
MDMA research were focused on its harmful effects (23–27).
The products sold on the illegal market as MDMA or „ecstasy“, widely vary in the purity 
of the product and commonly contain adulterants that may, in fact, be another entactogen 
(28, 29). Thus, in the earliest period, the name „ecstasy‘’ was a synonym for both MDA and 
MDEA, although the name „Eve‘’ is more often used for MDEA by vendors and users. The 
MDMA, MDEA and MDA are structural analogues with closely related chemistry and bio-
logical effects, therefore, properties attributed to MDMA, mostly apply to MDEA, and to a 
significant extent to MDA (30). 
Despite the abundance of literature data on the adverse effects of ecstasy, there is a 
widespread belief that ecstasy is a safe drug among teenagers and younger adults. However, 
„street drugs” that are very often sold under the name „ecstasy“ may contain other known 
but undeclared entactogen or even new one that also has serious acute and chronic toxic side 
effects that resemble those previously seen with other amphetamines. 
Serotonergic drugs (entactogens and hallucinogens) are associated with acute serotonin 
syndrome, hyperthermia, seizures, and hyponatremia (8). The ingestion and consequent 
toxicity of ecstasy misuse may result in serious or minor clinical symptoms depending on 
the individual patient, the dose administered, duration of the drug use, as well as the con-
comitant use of other drugs (22). Severe side-effects included sudden death, hyperpyrexia, 
rhabdomyolysis, multi-organ failure or isolated liver failure, serotonin syndrome, hypona-
traemia with cerebral edema and acute panic disorder, whereas minor clinical symptoms 
were related to a disturbance in the central and autonomic nervous system such as tachycar-
dia, hypertension, mydriasis, nystagmus, dry mouth, sweating, confusion, elevated mood 
and ataxia (23). Additionally, many other clinical symptoms and signs have been reported 
for regular ecstasy users e.g., intravascular coagulopathy, heart stroke, irritability, tremor, 
delirium, paranoia, depression, insomnia, loss of coordination and suicide (24–33). After the 
intake of usual recreational doses of 50 to 150 mg of ecstasy, blood concentration varies be-
tween 100–250 ng mL–1 or 100–250 μg L–1, and in most cases of serious toxicity or fatality, 
blood concentrations ranged from 0.5 to 10 mg L–1 (30). Blood levels, such as low as 0.11–0.55 
mg L–1, were also found in some intoxicated users, which almost overlapped recreational 
ranges, therefore other factors should also be taken into consideration of the seriousness of 
the effects, especially drug combinations and not only the concentration of ecstasy.
In the case of MDMA intoxication, there is no antidote (29), however, supportive care 
can be used. For example, in the control of agitation and anxiety or seizures, benzodiaze-
pines may be administered, in the case of hyperthermia, rapid cooling is a priority, whereas, 
in the case of severe hypertension, an antihypertensive drug may be administered (23).
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Oral use of ecstasy is the most common way of ingestion, after which a rapid absorption 
into the bloodstream occurs, and effects begin 30–60 min lasting up to 8 h (30). MDMA has 
also been detected in toxicological analyses of a suspected drug-facilitated sexual assault 
(DFSA) (34). The misuse of illicit drugs causes indisputable societal damage and signifi-
cantly increases health costs. Therefore, it is necessary to become well-informed with the 
usage levels and trends of these drugs in order to undertake the necessary actions to reduce 
this use. In several recent studies, it has been reported that illicit drugs are detectable in 
wastewater from municipal sewage treatment plants (STPs) and surface waters. This initi-
ated a new developmental approach, i.e., sewage epidemiology, for the estimation of illicit 
drug use based on measurements of urinary-excreted illicit drugs and their metabolites in 
untreated wastewater (35). This is possible since, after the consumption, these substances are 
excreted in urine and feces unchanged or as active metabolites in high percentages and 
continuously discharged into domestic wastewaters. Residues of illicit drugs can, therefore, 
reach STPs in substantial amounts, escaping degradation, and are then released into surface 
waters. Found environmental concentrations are low, but the risk for human health and the 
environment cannot be excluded. Among illicit drugs, the morphine, cocaine, methamphet-
amine and ecstasy all have potent pharmacological activities and their presence in surface 
waters may be toxic to aquatic organisms (36).
The results of the study of MDMA load in sewage and wastewater treatment plants 
(WWTPs) in Paris and its suburban areas revealed that the mean MDMA consumption in-
creases from 7.2 to 15.4 mg day–1 per young person between week and weekend and festive 
events (37). These values are rather low compared to findings in Italy, Spain, and the United 
Kingdom, countries with the highest consumption prevalence according to European Moni-
toring Centre for Drugs and Drug Addiction’s (EMCDDA’s). Thus, the most popular entac-
togens (MDA, MDMA and MDEA) were found in wastewater in north-eastern Spain in 
concentrations of 83, 46 and 28 ng L–1, respectively, and the increase of ecstasy concentration 
per day (approximately 4 doses per 1000 young adults 15–34 years old) especially during the 
weekend, highlighted the illicit drug use as a new environmental problem with potential 
impact on aquatic ecosystems (38).
MDMA is not the same as „ecstasy” or „molly” because substances sold on the street 
under these names may contain MDMA, but they frequently also contain unknown and/or 
dangerous adulterants (5, 15). In laboratory studies, pure MDMA has been proven sufficiently 
safe for human consumption when taken a limited number of times in moderate doses. 
Unfortunately, the same cannot be concluded for all entactogen molecules that can be sold 
on the illegal market instead of MDMA with largely unknown properties.
The aim of this study was to predict the ADMET properties of selected entactogens of 
the phenylethylamine type and their o-quinones, the main metabolites mediated by cyto-
chrome P450 enzymes, as well as to explore the relationship between molecular descriptors, 
ADMET properties and environmental toxicity parameters in order to highlight their impact 
on the environment and human health.
MATERIALS AND METHODS
The molecular descriptors (MDs) and ADMET parameters of investigated entactogens 
and their o-quinone-metabolites used in this in silico study were computed by ADMET 
PredictorTM (Simulations Plus Inc., USA, www.simulations-plus.com) (39). The basic chemical 
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structures of investigated entactogens and their o-quinone metabolites are displayed in 
Fig. 2 and in Table I, while 2D chemical structures, IUPAC names and SMILES (simplified 
molecular-input line-entry system) that were used for molecules entry input in the ADMET 
PredictorTM software of entactogen molecules and o-quinone metabolites are displayed in 
Supplementary material in Table S-1a and Table S-1b, respectively.
Statistical measurement and the prediction accuracy of ADMET Predictor’s models 
used in this study are displayed in Table S-2 to Table S-5 in Supplementary Material.
ADMET-related descriptors relevant to environmental toxicity were computed using 
the following aquatic toxicity models:
1) TOX_FHM, the fathead minnow acute toxicity model based on lethal effects on 
Pimephales promelas (Minnow_LC50) which predicts concentration in mg L–1 of a given com-
pound that will kill 50 % of a population of minnows after an exposure time of 96 hours 
(40); 
2) TOX_ATTP model which is based on the inhibition of protozoa species Tetrahymena 
pyriformis and predicts concentration in mmol L–1 of a given compound needed to inhibit 
50 % growth of T. pyroformis (Th_pyr_pIGC50) after approximately 40 hours exposure (41);
3) TOX_DM model which is based on lethal concentration (mg L–1) that results in the 
death of 50 % of Daphnia magna (water fleas) (Daphnia LC50) after 48 hours (42); 
4) TOX_BCF model, the environmental toxicity based on bioconcentration factor 
(BCF) which is the ratio of the chemical concentration in biota to that in water at steady 
state, as a result of absorption via the respiratory surface, i.e., describes the accumulation 
of pollutants partitioning from the aqueous phase into an organic phase (typically fish), 
BCF = (Concentration in organism)/(Concentration in environment) (43) and
5) TOX_BIODEG model, the percent of biodegradation (% BD = 100 × BOD/ThOD) 
based on which a compound is considered readily biodegradable (RB) if the biological 
oxygen demand (BOD) is greater than or equal to 60 % of the theoretical oxygen demand 
(ThOD), otherwise that compound is considered non-readily biodegradable (44).
The prediction accuracy and the statistical measurements of linear predictive models 
for the TOX_ATTP, TOX_FHM, TOX_DM and BCF are displayed in Table S-3 in Supple-
mentary material while the validation of the binary predictive model of 2D TOX_BIODEG 
is displayed in Table S-4, also in Supplementary material. 
The Metabolism module of ADMET PredictorTM (39, 45), composed of CYP substrate/
non-substrate classification models for CYP enzymes 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1 
and 3A4, their corresponding site of metabolism models (SOM) as well as kinetic parameter 
models (Km, Vmax and CLint) and CYP inhibition models for CYP1A2, 2C9, 2C19, 2D6, and 
Fig. 2. The general formula of investigated entactogens (left) and their o-quinone metabolites (right), 
with the same substituents R to R5 listed in Table I.
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3A4 were used for the prediction of metabolite pathways of investigated entactogens. This 
prediction tool was trained on the Accelrys Metabolite Database. This data set has been 
curated and further sources for metabolic reactions were added. Models for the prediction 
of SOMs were based on artificial neural network ensembles (ANNEs) derived using atomic 
descriptors to generate an artificial neural network classification (ANNC) model. For each 
atom of a molecule, a score (0−1) for the likelihood of a metabolic reaction to happen was 
assigned. A substrate classification model can predict whether a compound is a substrate of 
five CYP enzymes. 
Metabolites were generated using SMIRKS strings (a reaction transform language) to 
specify the transformations predicted by the SOM models. The CYP kinetic parameters were 
predicted from ANNE regression models. Statistical parameters for used toxicity and CYP 
metabolism binary predictive models of ADMET PredictorTM are displayed in Table S-5 in 
Supplementary Material.
All correlation analyses were performed using Origin Pro 8.0 software (Origin Labora-
tories, USA). 
RESULTS AND DISCUSSION
In this in silico study, a set of 25 selected entactogen molecules (Table I) was investigated 
by the ADMET PredictorTM with the aim to evaluate their safety profile and potential impact 
on the environment and health. Although many in vitro and in vivo studies have been made 
on MDMA metabolism and its precursor MDA, and their Phase I as well as Phase II me-
tabolites were fully characterized (22, 46–49), there are still limited available data about the 
metabolism of majority entactogens available on the illicit market. Therefore, in this study 
we explored ADMET properties of set of entactogens, including MDMA and its structural 
analogs (N = 25), as well as their o-quinone metabolites, with the aim to evaluate the poten-
tial environmental risk of these illicit drugs and to investigated the relationship between 
computed molecular descriptors (MDs), ADMET properties and related ecotoxicity para-
meters by QSAR studies. The molecular descriptors of parent entactogens (1–25) and their 
corresponding o-quinone metabolites (1-M1 to 25-M1) are displayed in Table II. The ADMET 
parameters of investigated entactogens and their o-quinone metabolites are summarized in 
Table III and Table IV, respectively. Data obtained for predicted CYP metabolic pathways of 
entactogens 1–25 with the involved CYP enzymes and the percentage of each metabolite are 
displayed in Table S-6-1 to Table S-6-3, while the comparative display of computed TOX_
Risks of investigated entactogens and their relative ecotoxicities, represented by pentagon 
plots, are displayed in Table S-7 in Supplementary Material. 
CYP metabolism – in silico approach
The predicted CYP metabolism of investigated entactogen molecules involves two 
main pathways (Fig. 3, Table S-6-1 to Table S-6-3) analogous to those already observed and 
detected in vitro and in vivo studies of MDMA metabolism (22, 46–49).
The O-demethylenation represents the main pathway which was predicted for almost 
all investigated molecules (96 %) with exception of 1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)
propan-2-amine (DiFMDA, 23) in which the 2,2-disubstitution enhanced the metabolic 
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stability of this drug (50). For this metabolic reaction the main cytochrome P450 enzymes, 
i.e., CYP1A2 and 2D6 were predicted with the highest probability, however, CYP2C9, 2C19 
and 3A4 were also predicted, but to significantly less extent (Table S-6-1).
As the CYP2D6 represents one of the major catalyzing enzymes in this reaction, and 
since it is an enzyme which is characterized by genetic polymorphism in humans, this meta-
bolic reaction might be of higher risk for acute entactogen’s toxicity in slow metabolizers (23, 
49). The risk of polymorphism may be diminished by the formation of an auto-inhibiting 
enzyme-metabolite complex and auto-inhibition which renders this toxicity in all subjects, 
regardless of genotype, and the limited effect of CYP2D6 pharmacogenetic variation on the 
acute toxicity was also observed in previous pharmacokinetic studies of MDMA (31).
Tabl I. Investigated entactogens 1–25
No. Entactogen R1 R1 R2 R3 R4 R5 R6 R7
1 MDA H H H CH3 H H H H
2 MDMA H H CH3 CH3 H H H H
3 MDDM CH3 CH3 CH3 CH3 H H H H
4 MDEA H H CH2CH3 CH3 H H H H
5 MDPR H H CH2CH2CH3 CH3 H H H H
6 MDBU H H CH2CH2CH2CH3 CH3 H H H H
7 MDIP H H CH(CH3)CH3 CH3 H H H H
8 MDAL H H CH2CH = CH2 CH3 H H H H
9 MDPL H H CH2C≡CH CH3 H H H H
10 MDCPM H H CH2-C3H5a CH3 H H H H
11 MDBZ H H CH2C6H5 CH3 H H H H
12 MDOH H H OH CH3 H H H H
13 MDHOET H H CH2CH2OH CH3 H H H H
14 MDMEO H H OCH3 CH3 H H H H
15 MDMEOET H H CH2CH2OCH3 CH3 H H H H
16 BDB H H H CH2CH3 H H H H
17 MBDB H H CH3 CH2CH3 H H H H
18 Ethyl-K H H CH2CH3 CH2CH2CH3 H H H H
19 5-MeMDA H H H CH3 H CH3 H H
20 MMDA H H H CH3 H OCH3 H H
21 MMDA-2 H H H CH3 OCH3 H H H
22 MMDPEA H H H H H OCH3 H H
23 DiFMDA H H H CH3 H H F F
24 EIDA H H H CH3 H H CH3 H
25 2,3-MDA H H H CH3 H H H H
a CH2-cyclopropyl
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 1-M1 1 mi 1 mi 0 0 36
 2-M1 0.12 1A2 0.12 1A2 0 0 24
 3-M1 0.84 1A2, mi 0.84 1A2, mi 0 0 31
 4-M1 1 Hp 0 0 1 Hp 42
 5-M1 0 0 0 0 52
 6-M1a 0 0 0 0 48
 7-M1 0 0 0 0 43
 8-M1 0 0 0 0 68
 9-M1 0 0 1 S535 0 45
10-M1 0.52 2D6 0.52 2D6 1 S_97 0 62
11-M1 1 2D6 1 2D6 0 0 52
12-M1 1 Mu 0 1.5 S_97, S100 1 Mu 36
13-M1 0 0 0 0 31
14-M1 3 Hp, Mu, 1A2 1 1A2 1.5 S100, m535 2 Hp, Mu 36
15-M1 0 0 0 0 26
16-M1 1 mi 1 mi 0 0 56
17-M1 1 Hp 0 0 1 Hp 36
18-M1 1 Hp 0 0 1 Hp 60
19-M1 1 mi 1 mi 0 0 39
20-M1 0 0 0 0 9
21-M1 0 0 0 0 19
22-M1 0 0 0 0 12
23-M1 Np Np Np Np Np Np Np Np –
24-M1 1 mi 1 mi 0 0 15
25-M1 1 mi 1 mi 0 0 28
mi – midazolam inhibition, Hp – hepatotoxicity, Mu – mutagenicity, 1A2 and 2D6 – CYP 1A2 and CYP 2D6, S_97, 
S100, S535 af m535 – predicted mutagenicity, Np – not predicted
By further oxidation steps, the formed O-demethylenated metabolites produced o-qui-
none metabolites in all studied entactogens except for DiFMDA (23). These metabolites were 
predicted in the yields ranging from 15 to 68 % (Table IV, Table S-6-1).
The other important pathways that correspond to oxidative N- or O-dealkylation to 
corresponding amine or hydroxylamine metabolites were predicted for 18 entactogens (72 
%), i.e., 2–11, 13–15, 17, 18, 20, 24 and 25). Both these reactions were catalyzed by almost the 
same enzymes, i.e., CYP1A2 and 2D6 with higher probability, and also by CYP2C9, 2C19 and 
3A4, however with significantly less extent.
The oxidative deamination to corresponding carbonyl metabolites was predicted for 10 
entactogens (40 %, i.e., 1, 2, 12, 16, 19–25) while the N-hydroxylation of formed amines to 
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Fig. 3. Predicted biotransformation pathways of investigated entactogens 1–25 mediated by CYP 
enzymes using Simulations PlusTM Metabolite module.
corresponding hydroxylamine metabolites were predicted in metabolic pathways of the six 
entactogens (24 %, i.e., 1, 19–23) (Fig. 3, Table S-6-1). 
All other pathways that involve either hydroxylation of alkyl chain (5, 6, 10, 15, 19, 20, 
22–25, Table S-6-2) or aromatic moiety (11, 13, 19–22 in Table S-6-3) or oxidation of already 
formed hydroxylamine (12, Table S-6-3) were specific for particular entactogen and were 
predicted mostly to less extent as minor metabolites.
As expected, the lipophilicity (MlogP) computed according to the method by Moriguchi 
et al. (53), the parent entactogen molecules were revealed as more lipophilic (MlogP 0.84–2.98) 
in comparison to their corresponding o-quinone metabolites (MlogP 0.04–2.22). The same 
was revealed for other lipophilicity parameters, i.e., S+logP and logBB (the logarithm of the 
brain/blood partition coefficient) (Table II). The opposite was found for o-quinone metabo-
lites in terms of their water solubility (S+Sw) for which the predicted scores were almost 
doubled, i.e., with the S+Sw in the range from 1.30 (11-M1) to 52.85 (22-M1) while for their 
parent molecules S+Sw was computed in the range from 0.54 (11) to 23.85 (22) (Table II).
Prediction of the tissue distribution of investigated entactogen molecules is important 
not only in the drug development but also in the evaluation of toxicokinetics, therefore the 
volume of distribution (Vd) and the descriptors describing the blood-brain barrier (BBB) pene-
tration such as logBB are valuable in the evaluation of these drugs (51). The investigated en-
tactogens possess volume of distribution (Vd/dm3 kg–1) in the range of 0.88–3.77 dm3 kg–1 and 
the highest value was computed for DiFDMA (23) what was revealed as one of the ADMET 
risks for this entactogen, and the lowest for MDMEO (14) in a set of parent entactogens. In a 
set of o-quinone metabolites, the Vd was ranged from 0.66 (14-M1) to 2.29 dm3 kg–1 (11-M1).
The logarithm of the blood-brain partition coefficient (logBB) were computed for the 
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for MDOH (12) and the highest for MBDB (17), while for o-quinone metabolites this para-
meter was computed from –0.26 to 0.35 with the lowest value predicted for o-quinone of 
MDOH (12-M1) and the highest for o-quinone metabolite of Ethyl-K (18-M1). The jejunal 
permeability, S+Peff were computed in the range from 1.92 (23) to 6.57 (14) in a set of parent 
entactogen molecules, while in the set of o-quinone metabolites, the S+Peff ranged from 1.12 
(21-M1) to 4.07 (14-M1). 
All three parameters (S+Peff, logBB and Vd) were somewhat lesser in the set of o-quinone 
metabolites than in the set of parent entactogens.
ADMET analysis
The main purpose of the in silico predictions of ADMET properties of compounds is the 
prediction of their in vivo biokinetics (54) since a good ADMET profile of a drug is necessary 
as a good biological property of that drug.  In order to predict ADMET properties of the in-
vestigated entactogens and their o-quinone metabolites, we used the ADMET PredictorTM.
In order to explore if there are excessive ADMET disadvantages for these molecules, the 
ADMET Risk module was applied. The predicted ADMET properties of investigated entac-
togen molecules (1-25) (Table III) were compared with their corresponding o-quinone me-
tabolites 1-M1 to 25-M1, with exception of the o-quinone metabolite of 23 that was not pre-
dicted (Table IV).
The ADMET_ Risk, a measure that corresponds to overall risk due to absorption, distri-
bution, metabolism and excretion, was ranged from 0.48 (8) to 3.00 (15) (Table III) for entac-
togen molecules, whereas for o-quinone metabolites it ranged from 0.00 (5–9, 13, 15, 20–22) 
to 3.00 (14) (Table IV). For comparison, ADMET Risk is larger than 6.5 for about 10 % of the 
drugs comprised in World Drug Index (WDI) in which 10 % of drugs violate more than six 
of the default rules (39).
Toxicity was estimated by two ADMET risk models: TOX_MUT Risk and TOX_Risk 
module. TOX_MUT Risk is a summary of the outputs of the ten different TOX_MUT models 
that independently predict the mutagenicity expected for five strains of S. typhimurium with 
and without microsomal activation. The TOX_Risk model consists of seven rules of different 
toxicities.
The mutagenicity (Mu) was predicted for MDMEO (14) and o-quinone metabolites of 
MDOH (12-M1) and MDMEO (14-M1), whereas the hepatotoxicity (Hp) was predicted in the 
set of o-quinones for the MDEA (4-M1), MDMEO (14-M1), MBDB (17-M1) and Ethyl-K (18-M1).
In addition to the mutagenicity (Mu) and hepatotoxicity (Hp), the clearance of cyto-
chrome P450 catalyzing enzymes, i.e., CYP1A2, 2C19, and 2D6 was also revealed as CYP 
risks in a set of entactogens (Table III), whereas in a set of o-quinone metabolites in addition 
to Mu and Hp the CYP risk due to clearance of 1A2 and the midazolam inhibition (mi) for 1, 
3, 16, 19, 24 and 25 were revealed. 
Among the investigated entactogen molecules, the MDMEO (14) was revealed as the 
molecule with the worst predicted safety profile (Fig. 4), since the mutagenicity (Mu) was 
predicted for both, parent entactogen MDMEO (14) and its o-quinone metabolite (14-M1), 
and both molecules can be metabolized to o-quinone 12-M1 for which mutagenicity was also 
predicted. For the o-quinone metabolite 14-M1 the hepatotoxicity (Hp) has also been pre-
dicted.
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Environmental toxicity evaluation – in silico approach
The results of models useful for the evaluation of environmental toxicity, i.e., the acute 
toxicity in Tetrahymena pyriformis (TOX_ATTP expressed as Th_pyr_pIGC50 in mmol L–1), 
the acute toxicity in Pimephales promelas, the fathead minnow (TOX_FHM expressed as 
Minnow LC50 in mg L–1) and the acute toxicity in Daphnia magna (TOX_DM expressed as 
Daphnia_LC50 in mg L–1) as well as bioconcentration factor (BCF) and biodegradability 
(TOX_Biodeg) of entactogen molecules (1–25) and corresponding o-quinone metabolites 
(1-M1–25-M1) are displayed in Table V. The investigated entactogens 1–25 were revealed 
as non-biodegradable molecules (estimated Biodegradn – No 96 %) while the majority of 
their o-quinone metabolites (1-M1–18-M1, 22-M1 and 24-M1) were predicted as biodegra-
dable (Yes 58–87 %) with the exception of o-quinones 19-M1–21-M1, 23-M1 and 25-M1. 
Likelihood of a chemical’s biodegradation in the environment for investigated entactogens 
and their metabolites was predicted based on quantitative structure-biodegradability re-
lationship (QSBR) models, the combinatorial classification probability models of ready 
biodegradability (RB) versus not ready biodegradability (NRB) of chemicals that are based 
on the largest Japanese MITI data set (52).
The predicted scores for bioconcentration factor (BCF) of the investigated entactogens 
were computed in the range from 4.64 to 68.66, while for their o-quinones were computed 
in the range from 1.66 to 3.23. These findings imply the conclusion that the accumulation 
of o-quinone metabolites, will be with lesser partitioning between the aqueous phase and 
the organic phase (typically fish) in comparison to their parent entactogens.
The acute environmental toxicities were computed as follows:
a) for entactogens the TOX_FHM in the range from 2.65 (11) to 172.27 (13) mg L–1, 
TOX_ATPP from –0.62 (18) to 1.17 (11) mmol L–1 and TOX_DM from 0.60 (9) to 29.11 (3) mg L–1,
b) for o-quinone metabolites the TOX_FHM in the range from 0.21 (8-M1) to 2.30 (22-
M1) mg L–1, TOX_ATPP from –0.83 (13-M1) to 0.45 (11-M1) mmol L–1 and TOX_DM from 
0.95 (9-M1) to 177.98.11 (3-M1) mg L–1.
Fig. 4. Entactogen molecule MDMEO (14), and its o-quinone metabolite of MDMEO (14-M1) and the 
o-quinone metabolite of MDOH (12-M1) for which the mutagenicity (Mu) has been predicted and o-
quinones of MDEA (4-M1), MDMEO (14-M1), MBDB (17-M1) and Ethyl-K (18-M1) for which the 
hepatotoxicity (Hp) has been predicted.
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Based on the predicted biodegradability as well as the obtained computed scores for 
TOX_FHM, TOX_ATTP, TOX_DM and TOX BCF for the set of entactogen molecules 1–25 
and the set of their o-quinone metabolites (1-M1 to 25-M1), it can be concluded that o-qui-
none metabolites are more ecotoxic comparing to their parent entactogens.
Quantitative structure activity relationship (QSAR)
The computed molecular descriptors (MDs), ADMET properties and parameters rele-
vant to environmental toxicity were used in this QSAR study. The best correlations were 
obtained with MlogP which was computed in the range between 0.84 and 2.98 for entacto-
gen molecules and for corresponding o-quinone metabolites MlogP was computed in the 
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Fig. 5. The relationship of the MlogP of entacto-
gens (with exception of 23) and MlogP of o-qui-
none metabolites.
Fig. 6. The relationship of the MlogP of entacto-
gens and their toxicity against T. pyriformis ex-
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Fig. 7. The relationship of the MlogP of entacto-
gens (12 and 13 excluded) and their predicted 
toxicity against fathead minnow expressed as 
Minnow_LC50 (mg L–1).
Fig. 8. The relationship of the MlogP of o-quinone 
metabolites and their predicted toxicity against 
fathead minnow expressed as Minnow_LC50 (mg 
L–1).
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Fig. 9. The relationship of the MlogP of entacto-
gens (3 and 11 excluded) and their bioconcentra-
tion factors (BCF).
Fig. 10. The relationship of the MlogP and the bio-
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0.0 1.5 2.01.00.5 0.51.0
Fig. 11. The relationship of the MlogP of entacto-
gens (with exception of 23) and the percentage 
(%) of o-quinone metabolites’ yields. 
Fig. 12. The relationship of the MlogP and the 
percentage (%) of o-quinone metabolites’ yields.
in a significant linear correlation with the MlogP of their corresponding o-quinone meta-
bolites (R = 0.99) (Fig. 5).
A significant linear correlation (R = 0.94) obtained between MlogP of entactogens against 
TOX_ATTP expressed as Th_pyr_pIGC50 (the lethal concentration that results in the death of 
50 % of protozoa species Tetrahymena pyriformis) is displayed in Fig. 6. The highest Th_pyr_
pIGC50 scores were obtained for N-(1-(benzo[d][1,3]dioxol-5-yl)propan-2-yl)hydroxyl-amine 
(MDOH, 12) and N-(1-(benzo[d][1,3]dioxol-5-yl)propan-2-yl)-O-methylhydroxylamine (MD-
MEO, 14), which might suggest that the presence of N-O bond in the entactogen structure 
reduces toxicity against T. pyriformis as was the case with increase of lipophilicity.
QSAR studies also revealed a significant linear correlation between MlogP and TOX_
FHM expressed as Minnow_LC50 computed for entactogens and o-quinone metabolite (Fig. 
7 and Fig. 8, respectively). One can observe that, with the increase of lipophilicity, either 
in the set of entactogens or in the set of their o-quinone metabolites, the toxicities against 
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fathead minnow also increase, and o-quinone metabolites showed to be more toxic be-
cause they can produce the same lethal effect in smaller concentrations. 
Linear relationships were also observed between MlogP and bioconcentration factors 
(BCFs) of entactogens and BCFs of their o-quinone metabolites (Fig. 9 and Fig. 10, respec-
tively). The risk of bioconcentration factor (BCF) increases with the increase either with 
lipophilicity of entactogens or o-quinone metabolites. 
Although, with somewhat lesser coefficient correlations, the linear relationships were 
also found between MlogP either of entactogens or MlogP of their corresponding o-qui-
none metabolites with the predicted percentage of o-quinone metabolites’ yields.
No significant correlations were found between MlogP and TOX_DM expressed as 
Daphnia LC50.
Statistical data of the linear correlations and linear fit obtained by OriginPro8 be-
tween MlogP and ecotoxic and other parameters of investigated entactogens and their 
corresponding o-quinone metabolites are displayed in Table VI.
CONCLUSIONS
Many toxicants, including drugs, are present in our environment, and in the case of 
lack of their toxic data, the in silico methods of toxicokinetics can provide useful informa-
tion for integration chemical toxicity and exposure estimation in order to predict potential 
chemical, biochemical and environmental risks. In this in silico study, a set of 25 selected 
entactogen molecules and their corresponding o-quinone metabolites were analyzed by 
the ADMET PredictorTM software with the aim to evaluate their ADMET profile and po-
tential risk impact on the environment and consequently on human health. 
For many of entactogens included in this study, there are limited available data on 
their metabolism and their potential environmental risks.
The evaluated entactogens have been revealed as non-biodegradable molecules while 
the majority of their corresponding o-quinones were revealed as biodegradable metabolites.
In silico study of CYP-metabolism of the investigated entactogens was characterized 
by two main metabolic pathways analogous to those already observed and detected in 
vitro and in vivo studies of MDMA metabolism. The first pathway is O-demethylenation 
which was predicted for almost all investigated molecules (96 %) with an exception of 
1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)propan-2-amine (DiFMDA, 23) in which the 2,2-di-
substitution enhanced the metabolic stability of this drug.
For this reaction the main cytochrome P450 enzymes CYP1A2 and 2D6 were pre-
dicted with the highest probability, however, CYP2C9, 2C19 and 3A4 were also predicted, 
but to a significantly less extent. The O-demethylenated metabolites were capable of pro-
ducing o-quinone metabolites by further oxidation steps and these metabolites were pre-
dicted for almost all investigated entactogens with exception of DiFMDA, 23).
The other important pathways that correspond to oxidative N- or O-dealkylation, 
both catalyzed mostly by CYP1A2 and 2D6 with a higher probability, and also by 2C9, 
2C19 and 3A4, but to a significantly less extent, to the corresponding amine or hydroxyl-
amines metabolites were predicted for 18 entactogens.
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The oxidative deamination to corresponding carbonyl metabolites was predicted for 
10 entactogens while the N-hydroxylation of formed amines to corresponding hydroxyl-
amine metabolites were predicted in metabolic pathways of 6 entactogens. 
All other pathways that involve either hydroxylation of alkyl chain or aromatic moiety 
or oxidation of yielded hydroxylamine were specific for particular entactogen and were 
predicted mostly to less extent as minor metabolites. 
As expected, parent entactogen molecules were revealed with higher lipophilicity 
(MlogP) in comparison to their corresponding o-quinone metabolites. The opposite was 
found for o-quinone metabolites in terms of their water solubility (S+Sw) for which the 
predicted scores were almost doubled in comparison to their parent molecules.
The predicted ADMET properties of investigated entactogen molecules were com-
pared with the ADMET properties of their o-quinone metabolites. The ADMET_Risk, 
which corresponds to overall risk due to absorption, distribution, metabolism and excre-
tion, showed entactogen molecules as the least favourable. The mutagenicity (Mu) was 
predicted for MDMEO (14) as well as for the o-quinone metabolites of MDOH (12-M1) and 
MDMEO (14-M1), while the hepatotoxicity (Hp) were predicted in the set of the o-quinones 
for MDEA (4-M1), MDMEO (14-M1), MBDB (17-M1) and Ethyl-K (18-M1). 
In addition to these risks the clearance of CYP catalyzing enzymes 1A2, 2C19, and 2D6 
were also revealed as a CYP risk while in the set of o-quinone metabolites in addition to 
Mu and Hp the CYP risk due to clearance of 1A2 and the midazolam inhibition (mi) for 
some metabolites was revealed. 
Among the investigated entactogen molecules, the MDMEO (14) was revealed as the 
molecule with the least favourable predicted safety profile for which the mutagenicity 
(Mu) was predicted for both, parent molecule, i.e., MDMEO (14) and its o-quinone metabo-
lite (14-M1) for which the hepatotoxicity (Hp) was also predicted. In addition, both parent 
molecule and its o-quinone metabolite can be metabolized to o-quinone 12-M1 for which 
mutagenicity was also predicted. 
The four models useful for evaluation of environmental toxicity, i.e., the acute toxicity 
in Tetrahymena pyriformis (TOX_ATTP), the acute toxicity in Pimephales promelas, the fat-
head minnow (TOX_FHM) and the acute toxicity in Daphnia magna (TOX_DM) as well as 
bioconcentration factor (BCF) and biodegradability of entactogen molecules and corre-
sponding o-quinone metabolites were used. Based on the predicted biodegradability, as 
well as on obtained computed scores for TOX_FHM, TOX_ATTP, TOX_DM and TOX BCF 
for the set of entactogen molecules 1–25 and the set of their o-quinone metabolites (1-M1 
to 25-M1), it can be concluded that o-quinone metabolites are more ecotoxic comparing to 
their parent entactogens.
The computed molecular descriptors (MDs), ADMET properties and parameters rele-
vant to environmental toxicity were used in the QSAR study. The best correlations were 
obtained with MlogP with environmental toxic parameters TOX_FHM, TOX_ATTP, BCF and 
also with the predicted percentage of o-quinone metabolites yields which can be useful in 
further predictions of these properties for any new entactogen molecule or its metabolite.
Supplementary Materials are available upon request.
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